Immunic, Inc.
IMUX
$15.37
-$0.04-0.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.80% | 17.99% | 16.10% | 10.68% | 7.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.56% | 5.28% | 10.16% | 12.41% | 5.37% |
| Operating Income | -8.56% | -5.28% | -10.16% | -12.41% | -5.37% |
| Income Before Tax | -8.19% | 3.32% | -6.34% | -6.85% | 1.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.19% | 3.32% | -6.34% | -6.85% | 1.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.19% | 3.32% | -6.34% | -6.85% | 1.56% |
| EBIT | -8.56% | -5.28% | -10.16% | -12.41% | -5.37% |
| EBITDA | -8.56% | -5.25% | -10.13% | -12.37% | -5.32% |
| EPS Basic | 47.20% | 24.99% | 26.97% | 32.84% | 48.17% |
| Normalized Basic EPS | 48.12% | 22.04% | 23.95% | 30.58% | 46.74% |
| EPS Diluted | 47.20% | 24.99% | 26.97% | 32.84% | 48.17% |
| Normalized Diluted EPS | 48.12% | 22.04% | 23.95% | 30.58% | 46.74% |
| Average Basic Shares Outstanding | 74,505.68% | 46.85% | 43.59% | 39.70% | 75.22% |
| Average Diluted Shares Outstanding | 74,505.68% | 46.85% | 43.59% | 39.70% | 75.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |